Medizone International Files For Additional Bio-Terrorism Countermeasures Patent Protection

SAN FRANCISCO, Sept. 9 /PRNewswire/ — Medizone International,
Inc. (OTC Bulletin Board, OTCQB: MZEI) announces it has filed an
additional international patent application covering recent
developments in its variant of AsepticSure™ designed for
government use in bio-terrorism countermeasures. The
application, filed under the Patent Co-operation Treaty, extends
coverage to over 120 countries, including all major industrialized
countries for this government variant of the AsepticSure™
sterilization system.

Medizone’s CEO Edwin Marshall stated, “Through the development
process for our AsepticSure™ system, we have continued to
discover new applications the system appears well suited for. Each
application benefits from enhancements for the specific use
intended. While our prior patent filings cover the initial
discoveries and system function, we believe this filing offers a
significant enhancement of intellectual property protection for
this specific application. This is a step toward building a patent
fence around our primary patents that we believe greatly enhances
the company’s intellectual property protection for the government
market.”

Medizone International, Inc., is a research and development
company engaged in developing its AsepticSure™ System to
decontaminate and sterilize hospital surgical suites, emergency
rooms, intensive care units, schools and other critical
infrastructure. A government variant is being developed for
bio-terrorism countermeasures.

This Press Release contains certain forward looking statements
that involve substantial risks and uncertainties, including, but
not limited to, the results of ongoing clinical studies, economic
conditions, product and technology development, production
efficiencies, product demand, competitive products, competitive
environment, successful testing and government regulatory issues.
Additional risks are identified in the company’s filings made with
the Securiti

‘/>”/>

SOURCE